Klotho: The Longevity Protein

A circulating protein named after the Greek goddess of life-thread spinning. Overexpression extends mouse lifespan ~30%; deficiency accelerates aging. In 2026, multiple human trials are testing whether boosting Klotho is therapeutically viable.

🔬 Klotho has the strongest preclinical longevity data of any single protein. The 2026 question is whether you can raise it in humans without infusing the protein continuously — and whether doing so produces measurable healthspan changes within trial timelines.

Mouse Lifespan
Extension (Overexpr.)

AKL003 Phase 1b
Volunteers (2026)

Minicircle Gene-Tx
Persistence Target

Mechanism of Action

How It Works

🧬

Anti-FGF23 Co-Receptor

Klotho is an obligate co-receptor for fibroblast growth factor 23 (FGF23) in renal phosphate handling. The shed extracellular domain (sKlotho) circulates and acts independently as an anti-aging signal.

🛡️

Wnt & IGF-1 Modulation

sKlotho dampens excessive Wnt signaling (linked to senescence) and inhibits IGF-1 receptor signaling — both pathways implicated in aging and age-related disease.

🧠

Brain & Cognitive Effects

Single dose of αKL-F (a Klotho fragment) enhances cognition and synaptic plasticity in aged primates. Higher endogenous Klotho correlates with better human cognition in observational studies.

❤️

Cardiovascular & Renal

Klotho-deficient mice show vascular calcification, sarcopenia, hypogonadism, and emphysema. Higher Klotho associates with reduced cardiovascular events in aging cohorts.

Data

What the Data Shows

Mouse Lifespan Extension (Overexpression)

Kuro-o lab, Klotho transgenic vs WT

~30%

Klotho Decline With Age (Human)

Serum sKlotho falls steadily after age 40

Documented

Cognitive Boost After Single αKL-F (Primates)

Aged rhesus working-memory tasks

Acute

AKL003 mRNA Phase 1b

Klothea Bio — IV mRNA, 21 healthy volunteers, 2026

Active

Human Lifespan Data on Klotho Augmentation

Direct evidence

None Yet

Bottom Line

Key Takeaways

✅ What We Know

Discovered by Makoto Kuro-o; mouse Klotho overexpression extends lifespan ~30%
Acts as obligate FGF23 co-receptor; shed soluble form (sKlotho) acts as a circulating anti-aging signal
Klotho declines progressively with human age and correlates with healthspan biomarkers
Klothea Bio launched phase 1b of AKL003 (IV mRNA Klotho therapy) in February 2026
Minicircle is developing a Klotho plasmid gene therapy (subcutaneous) targeting ~1-year expression
Klotho Neurosciences (NASDAQ: KLTO) developing diagnostic "Klotho Clock"

⚠️ What We Don't Know

Whether raising Klotho in healthy humans extends lifespan or healthspan
Optimal therapeutic format — infused protein vs mRNA vs gene therapy
Long-term safety of chronic Klotho elevation (interactions with FGF23 and phosphate balance)
Whether oral/exercise-induced Klotho elevation produces clinical benefit
Translation from rodent models to humans (a recurring longevity-research caveat)

FAQ

Frequently Asked Questions

What is Klotho?

Klotho is a circulating anti-aging protein discovered by Makoto Kuro-o in 1997. The α-Klotho gene encodes a single-pass transmembrane protein expressed primarily in kidney, parathyroid, and brain. Its extracellular domain is shed as soluble Klotho (sKlotho) that circulates and acts on distant tissues. Mouse overexpression extends lifespan ~30%; deficiency causes accelerated aging.

Can humans take Klotho supplements?

No oral Klotho supplement has been validated. Klotho is a 130 kDa protein and would not survive digestion. Therapeutic strategies in active human development use IV mRNA (Klothea Bio AKL003), subcutaneous plasmid gene therapy (Minicircle), and small-molecule Klotho enhancers — all investigational. Exercise and certain calorie-restriction protocols modestly raise endogenous Klotho.

What human trials are running in 2026?

Klothea Bio launched a phase 1b randomized double-blind placebo-controlled trial of AKL003, an IV alpha-Klotho mRNA therapeutic, in February 2026. The study enrolls 21 healthy adults aged 25–75 at the GARM Clinic in Honduras, with two IV doses ~4 weeks apart. Endpoints include safety, tolerability, circulating sKlotho levels, and exploratory healthspan biomarkers.

Is the Minicircle Klotho gene therapy real?

Yes. Minicircle uses a non-integrating plasmid delivered via subcutaneous fat injection that drives Klotho expression for approximately one year per treatment. A proof-of-concept trial is underway with broader rollout in 2026. It is investigational, paid out-of-pocket, and outside conventional FDA regulatory pathways (offered in jurisdictions with permissive medical-tourism frameworks).

Does exercise raise Klotho?

Yes — modestly. Acute aerobic exercise raises serum sKlotho transiently; chronic exercise training elevates baseline sKlotho in older adults. Magnitudes are small relative to therapeutic strategies but represent the most accessible lever today.